TGF-β suppresses type 2 immunity to cancer
Nature, Published online: 21 October 2020; doi:10.1038/s41586-020-2836-1
Depletion of transforming growth factor-β receptor 2 (TGFBR2) in CD4+ T cells results in IL-4-dependent vascular remodelling, stopping tumour growth in a transgenic mouse model of breast cancer, suggesting that type 2 immunity could be targeted for cancer treatments.
Comments
Post a Comment